Grants for Native American tribal organizations - Federal

This grant provides funding to U.S. nonprofit organizations, academic institutions, and Native American tribes to create online editions of historical records, particularly focusing on the experiences of Black, Indigenous, and People of Color.

The U.S. Department of Justice (DOJ), Office of Justice Programs (OJP), Bureau of Justice Statistics (BJS) is seeking applications for funding. OJP is committed to advancing work that promotes civil rights and equity, increases access to justice, supports crime victims and individuals impacted by the justice system, strengthens community safety, protects the public from crime and evolving threats, and builds trust between law enforcement and the community. With this solicitation, BJS seeks to collect data on persons who died in the custody of federal law enforcement (LE) agencies in FY 24, FY 25, and FY 26, building on BJSs existing efforts. The data collection will include a web-based interface to allow federal LE agencies to identify all deaths that are arrest-related or that occur in detention or incarceration facilities. This program furthers the DOJs mission to uphold the rule of law, to keep our country safe, and to protect civil rights.

This funding opportunity is designed to establish a central hub that will support collaborative genetic research on Alzheimer’s disease and related dementias, focusing on diverse populations and innovative data-sharing practices.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative population-based research that can contribute to identifying and characterizing pathways and mechanisms through which work or occupation influences health outcomes and health status among populations with health and/or health care disparities, and how work functions as a social determinant of health.The main objective of this initiative is to determine the extent and mechanisms by which work as a SDOH both contributes to, and helps ameliorate, health and health care disparities. A recent workshop on September 28-29, 2020 organized by NIMHD (https://www.nimhd.nih.gov/news-events/conferences-events/hd-workshop.html) highlighted key ideas for furthering research on work as a SDOH that include conceptualizing work as a social class marker, as a source of exposures and risk factors, and as a source of beneficial social and economic resources such as income and wealth, neighborhood conditions, health care access, education, and social networks. Some key questions include: What are the specific and modifiable mechanisms by which work explains health disparities? To what extent does work as a social class marker, source of exposures and risk factors and/or source of beneficial social and economic resources explain health disparities? Which health disparities does work as a SDOH explain? Of particular interest are projects designed to examine pathways and mechanisms using conceptual model(s) grounded in minority health and health disparities theories that recognize that health disparities arise by multiple and overlapping contributing factors acting at multiple levels of influence (See the NIMHD Research Framework, https://www.nimhd.nih.gov/about/overview/research-framework.html). Studies must examine NIH-designated U.S. health disparity populations, e.g. racial and ethnic minority populations, sexual and gender minority groups, underserved rural populations, and socioeconomically disadvantaged populations of any race or ethnicity (https://www.nimhd.nih.gov/about/overview/). Studies involving primary data collection with human participants are strongly encouraged to incorporate SDOH measures from the Core and Specialty collections that are available in the Social Determinants of Health Collection of the PhenX Toolkit (www.phenxtoolkit.org). Of interest are intersectional approaches that consider different social identities and the embeddedness of individuals within families, households, and communities. Life course approaches that consider the role of work in shaping cumulative processes and critical transitions including periods of unemployment, under-employment, and unpaid and informal work arrangements, are also encouraged. Also, of interest is considering the role of work at the household level with influences on the health of partners and extended families, and the intergenerational transmission to children and their health. In addition, exploring the role of inequity-generating mechanisms that constrain choices around work and health such as racism and discrimination by sex, age, marital status, immigration status, social class, and other power structures is also encouraged. Additionally, of interest are projects that explore whether work can explain the health or health care disparities seen within diseases or conditions (e.g., COVID-19, opioid use disorder, mental/behavioral health, diabetes, cancer, heart disease, asthma, and maternal and infant health ) as well as disparities in co-morbidities and general indicators of health such as greater global burden of disease, quality of life, and daily functioning. Projects that utilize a syndemics lens (i.e., multiple disease states that are interlinked because of social, environmental, and structural conditions), to examine the role of work in disparities in co-occurring health conditions, are encouraged. Also, of interest are projects that explore how work contributes to health care disparities including but not limited to disparities in access to preventive, specialty, and emergency care, in health insurance coverage, and in quality of health care. Moreover, given the reciprocal relationship between work and health, of interest are projects that examine how health impacts access to different work opportunities, working conditions, and work benefits, and how that varies by different social identities. Projects may involve primary data collection and/or secondary analysis of existing datasets. Projects may utilize observational studies, natural experiments, quasi-experiments, simulation modeling, as well as use of large-scale longitudinal data sets, data mining techniques, registries, surveillance data, and linking to administrative data sets such as the Occupational Information Network (O*NET). Quantitative and mixed methods approaches are encouraged. Investigators are encouraged as appropriate for the research questions posed, to forge research collaborations with community partners and stakeholders in the conceptualization, planning and implementation of the research to generate better-informed hypotheses and enhance the translation of the research results into practice.

The grant titled "Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center" aims to fund a clinical trial that will identify and test interventions to slow or prevent the development of heart disease in young adults who are at low immediate but high lifetime risk, comparing the effectiveness of current guidelines, LDL-lowering therapy, and potentially other methods.

This funding opportunity supports researchers conducting multi-site clinical trials to evaluate complementary and integrative health approaches that combine physical and psychological therapies, aiming to gather essential data for future larger-scale studies.

Each funding opportunity description is a synopsis of information in the Federal Register application notice. For specific information about eligibility, please see the official application notice. The official version of this document is the document published in the Federal Register. Free Internet access to the official edition of the Federal Register and the Code of Federal Regulations is available on GPO Access at: http://www.access.gpo.gov/nara/index.html. Please review the official application notice for pre-application and application requirements, application submission information, performance measures, priorities and program contact information. For the addresses for obtaining and submitting an application, please refer to our Revised Common Instructions for Applicants to Department of Education Discretionary Grant Programs, published in the Federal Register on December 7, 2022. Purpose of Program: The EIR program, established under section 4611 of the Elementary and Secondary Education Act, as amended (ESEA), provides funding to create, develop, implement, replicate, or take to scale entrepreneurial, evidence-based (as defined in this notice), field-initiated innovations to improve student achievement and attainment for high-need students and to rigorously evaluate such innovations. The EIR program is designed to generate and validate solutions to persistent education challenges and to support the expansion of those solutions to serve substantially more students. The central design element of the EIR program is its multitier structure that links the amount of funding an applicant may receive to the quality of the evidence supporting the efficacy of the proposed project, with the expectation that projects that build this evidence will advance through EIRs grant tiers: Early-phase, Mid-phase, and Expansion. Early-phase, Mid-phase, and Expansion grants differ in terms of the level of prior evidence of effectiveness required for consideration for funding, the expectations regarding the kind of evidence and information funded projects should produce, the scale of funded projects, and, consequently, the amount of funding available to support each type of project. Early-phase grants must demonstrate a rationale (as defined in this notice). Early-phase grants provide funding for the development, implementation, and feasibility testing of a program that prior research suggests has promise, for the purpose of determining whether the program can successfully improve student achievement and attainment for high-need students. Early-phase grants are not intended to simply expand established practices or address needs unique to one particular context. Rather, the goal is to determine whether and in what ways relatively new practices can improve student achievement and attainment for high-need students. This notice invites applications for Early-phase grants only. The notices inviting applications for Mid-phase grants and Expansion grants are published elsewhere in this issue of the Federal Register. Assistance Listing Number (ALN) 84.411C.

This funding opportunity provides financial support for innovative research projects aimed at advancing the understanding and treatment of Alzheimer's disease and related dementias, inviting applications from a wide range of institutions and researchers.

Microbes and communities of microbes have remarkable genetic, physiological and biochemical diversity, allowing them to flourish in environments all over the planet and in a variety of substrates and hosts. Given their relative importance to ecosystems around the world, to the economy and to health, researchers have studied microbial systems extensively and have a better understanding of their capabilities and impacts on hosts and the environment. In recent years, researchers have increasingly turned to microbes and their diverse capabilities for bioremediation and applications in biotechnology, agriculture, and medicine. Because of advances in molecular biology, synthetic biology and bioengineering, researchers now have the ability to assemble synthetic microbial communities that have novel compositions, genetics and phenotypes and to use these communities to address both fundamental biological questions and a range of societal problems. The goal of this solicitation is to support research that addresses one or more of the three themes: 1) define the underlying mechanisms or rules that drive the formation, maintenance or evolution of synthetic microbial communities, 2) use synthetic microbial communities to address fundamental biological questions, including questions in molecular biology, cellular/organismal biology, ecology and evolution and/or 3) build synthetic communities with biotechnology, bioeconomy or environmental engineering applications, including but not limited to the production of novel biorenewable chemicals, biodegradation of recalcitrant or forever chemicals, enabling a circular bioeconomy, fostering sustainable agriculture and mitigating the impacts of climate change. For theme 3, the emphasis should be on designing communities with novel capabilities and understanding the underlying mechanisms that lead to these novel capabilities. Proposals must address one or more of the three themes noted above. Highest funding priority is given to proposals that have outstanding intellectual merit and broader impacts, while proposals with weaknesses in either category (or those that are perceived as likely to have an incremental impact) will not be competitive. The most competitive broader impacts include assessment plans. Well-conceived broader impacts activities take time and resources; thus, proposers are encouraged to include appropriate costs for broader impacts in the budget. To better understand the societal benefits and risks, as well as the potential for misuse or unintended damage to natural biological systems, synthetic microbial communities proposals should include a careful consideration of the social, ethical, and biosafety/security dimensions of the research. Investigators may choose to address these issues either as part of intellectual merit or broader impacts. Reproducibility in research leads to data that is amenable to more powerful analysis and the potential for reuse of data and greater generation of knowledge. Reproducibility in biological research that is prone to context dependent biological variation presents a unique challenge for the synthetic microbial communities researchers. Investigators must follow or advance best practices in sample collection and preparation, experimental design, data analysis, model generation, and/or validation of mathematical and computational methods to produce scientifically defensible results.

This funding opportunity supports researchers investigating the harmful effects of high-risk chemical exposures on lung and eye health, particularly in relation to public health emergencies.

This funding opportunity supports predoctoral students in dual-degree programs at institutions without NIH-funded training programs, helping them pursue research and clinical training to become future physician-scientists.

This funding opportunity is designed to support local governments, nonprofits, and educational institutions in Nebraska in providing culturally and linguistically appropriate health outreach and support services for newly arrived refugees.

This funding opportunity announcement (FOA) focuses on sensitivity and tolerance mechanisms underlying the development of alcohol use disorder. The intent of this FOA is to: (1) develop hypotheses about cellular, molecular or network mechanisms that regulate sensitivity and tolerance to alcohol, and (2) develop quantitative models to predict the development of tolerance and the progression to alcohol use disorder. These objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, clinical trial optional, in which secondary data analysis or pilot studies can occur during the R21 phase, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R21 phase.

This initiative will support national service centers for molecular structure determination by high resolution cryoelectron microscopy (cryoEM). The centers will provide access to state-of-the-art equipment, technical support, and training for the production and analysis of high-resolution data and offer equal-opportunity nationwide access to services through an open application process.

This funding opportunity provides financial support to various organizations for delivering essential services to victims of crime, including children, the elderly, and other affected individuals, across the United States.

This funding opportunity supports researchers exploring the mechanisms and effects of trained immunity in the immune system, particularly its implications for infectious diseases and immune-related conditions.

NIA intends to publish a Notice of Funding Opportunity (NOFO) soliciting applications that aim to develop Common Data Elements (CDEs) for Alzheimers disease (AD) and AD-Related Dementias (ADRD) using Real-World Data (RWD) from electronic health records and Centers for Medicare Medicaid Services (CMS) claims. The CDEs will foster data harmonization and interoperability among data systems that involve disparate and unaligned RWD. By reducing the efforts required for data harmonization in using RWD for cross-sectional and longitudinal analysis, the NOFO may enable researchers to utilize RWD more efficiently and produce real-world evidence in a faster manner. The NOFO is expected to be published in March 2024 with an expected application due date in June 2024. Please note that these time frames are simply estimations, and they may change. The NOFO is expected to utilize the Resource-Related Research Projects Cooperative Agreements (U24) activity code. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Additional details regarding the planned NOFO are below.

This grant provides funding for innovative preclinical research on radionuclide-based cancer therapies, focusing on their biological effects and potential combinations with other treatments, aimed at institutions and researchers in cancer biology and radiopharmaceuticals.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the continuation of NIDA's HIV Cohorts Program, encouraging existing and new sites to address new emerging and/or high priority research on multidisciplinary aspects of HIV/AIDS and substance abuse in alignment with NIH-HIV research priorities in order to inform policy or practice. Purpose The National Institute on Drug Abuse (NIDA) supports a program of longitudinal cohort studies that addresses the intersection of HIV and substance use. This program is a multidisciplinary platform to support basic, epidemiologic, and clinical research on HIV and HIV-associated co-morbidities and co-infections among populations with substance use and substance use disorders (SUDs) and to address research questions at the individual and population level. The purpose of this notice of funding opportunity (NOFO) is to support the continuation of NIDA's HIV Cohorts Program, encouraging existing and new sites to address new emerging and/or high priority research on multidisciplinary aspects of HIV/AIDS and substance use in alignment with NIH-HIV research priorities in order to inform policy or practice. Cohort sites supported under this program are required to report to and collaborate with a NIDA funded Coordinating Center, including participating in research agendas addressing NIDA’s high priority areas. Background Since the start of the HIV epidemic, cohort studies of people living with HIV (PLWH) and key populations at risk for HIV acquisition have made important contributions to the understanding of HIV virology, seroconversion dynamics, the natural and treated histories of HIV infection, the impact of HIV-associated co-morbidities (e.g., HCV) and complications including the role of substance use and SUDs. Longitudinal cohorts of at-risk individuals can provide crucial information about acute or early phases of infection, as well as disease transmission. Cohort studies provide a continuous source of data collection with the ability to address new or emergent public health problems, changes in drug use patterns and uptake of screening, prevention, or new treatments. Cohorts can also add to the understanding of processes such as aging, co-morbidities, social dimensions of HIV and substance use epidemics, as well as structural factors such as state and local policies, health insurance, and availability of relevant services. Research Objectives and Scope Research by each site should focus on high-risk populations or PLWH, who use substances. This RFA will seek applications from investigators working with HIV populations most affected by HIV (i.e., those at highest risk or living with HIV) in the United States. These can include sexual and gender minorities, racial/ethnic minorities, people involved in the criminal justice system and sex workers. Cohort populations should reflect social and economic characteristics of affected populations. Rural and metropolitan populations are welcome. This initiative also targets priority jurisdictions identified by the Ending the HIV Epidemic (EHE) initiative, although other jurisdictions will be considered with an epidemiologic justification (e.g., rural counties affected by opioid epidemics). Applicants must demonstrate the capacity to: Be responsive to changes to substance use and HIV epidemics, such as new substance use patterns, introduction of new substances; emergent co-morbidities including infectious diseases such as Mpox, COVID-19 and others, changes to public health policies, or to HIV/substance use treatments or prevention strategies. Applicants are strongly encouraged to include research that focuses on HIV-associated infectious co-morbidities (e.g., HCV, other sexual-transmitted disorders [STD]) and HIV-associated non-infectious co-morbidities, such as neurocognitive or other central nervous system impairment, mental health disorders and relevant medical disorders. [Note: The main focus of research should be the intersection of HIV and Substance Use, with co-morbidities as co-factors.] Partner with the end-user of the knowledge/data that would be generated (e.g., prevention specialists, Public Health officials, health departments, justice systems, policymakers, community organizations, etc.) and should thoroughly explain how the knowledge would be used to inform decisions and implement change. The involvement of the end-user is to ensure that the proposed data and methods will be useful. The partnerships with key end-users can be existing, or new relationships initiated based on success of previous stakeholder engagement and preparation to implement proposed work in a new setting. Collect data that can be used to inform policy and practice and include collaborations with potential end-users of cohort data such as those involved in HIV planning processes (e.g., EHE, Ryan White, CDC prevention funding) as well as service providers and provider organizations (e.g., health systems, federally qualified health centers [FQHCs], harm reduction sites). Participate in the collection of common data elements and biospecimens and participate in activities related to multi-site research such as data harmonization by working in concordance with the Data Coordinating Center. All sites are expected to collaborate and share all their data at least twice a year with the Data Coordinating Center. Assess variables that reflect system and structural factors that can affect HIV acquisition, utilization of prevention or treatment services, HIV viral suppression, substance use and/or factors that can influence dissemination of emergent prevention and care interventions. Research projects should address populations and research questions not captured by other HIV studies currently funded by NIH, including those co-funded by NIDA such as the WIHS/MACS Combined Cohort Study (MWCCS), the Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) or the NIAID Limited Interaction Targeted Epidemiology (LITE) cohorts while also being able to work with these outside cohorts on research questions where complementary of age, patterns of substance use, etc., may be desirable. Common Scientific Agenda and Collaboration with Data Coordinating Center: All sites are expected to collaborate and share all their data, at least twice a year, with the Data Coordinating Center at the University of Washington which will provide technical assistance, support, and resources. Clinical data and biological samples collected via the cohort(s) are expected to be available for sharing and use by the scientific community. Sites will also be expected to participate in collaborative activities including at least one annual meeting and monthly/quarterly conference calls with the Data Coordinating Center. Common Scientific Agenda All sites are also expected to participate in a common scientific agenda. The scientific areas listed below outline high priority research areas for NIDA that should be accomplished by each site during the five-year award period. There needs to be a clear justification of the clinical assessments, specimen collections, surveys and other measures, the frequency of participant visits and sampling from the cohort studies. Applications may propose additional research areas that are contemporary and are of high significance to the cooccurring HIV and substance use epidemics. Substance use and SUDs: drug use trends, types of drug use and frequency in relation to HIV risk and outcomes, risks associated with overdose related death HIV-related co-morbidities (HCV, Neurocognitive disorders) COVID-19; MPox and other sexually transmitted disorders), medical consequences, epidemiology, prevention, treatment, and outcomes in acute and chronic HIV Implementation: HIV and SUD services, uptake, and delivery. Point-of-care rapid testing, referral, and treatment, geocoding HIV viral loads: in relation to substance use, treatment, and co-morbidities Treatment: HIV and SUD treatment uptake and adherence, linkage to care Social determinants of health: socioeconomic factors, social support, trauma/violence, stigma, discrimination, life transitions, and food insecurity and the mechanisms of action through which they may affect health outcomes among people living with or at risk of HIV acquisition Brain and CNS: behavioral and psychiatric abnormalities, neurocognitive alterations in the context of substance use and HIV Genomic and phenotypic data in the context of HIV, co-morbidities, and substance use Research Strategy: Sites funded under this RFA will serve as a national resource for research addressing the intersection of HIV and substance use in the United States. Applications should include multidisciplinary teams and should select key populations at risk for HIV acquisition or populations of PLWH. Variables should reflect substance use in the study population with particular attention to its relevance for HIV acquisition, transmission, response to HIV treatment and/or viral suppression. Studies should address variables related to policy and practice such as HIV, substance use and other health care/public health service utilization, health insurance, key HIV risk populations and PLWH, people who experience marginalized social and sexual identities. Data collection should address stigma and discrimination as well as resource constraints (e.g., food, shelter, access to reliable transportation, access to reliable and private internet connectivity), particularly those which may limit participation in public health or health care services. Data collection should reflect current best clinical and methodologic practices and can include biospecimen collection, behavioral data from surveys or interviews, electronic health records and other methods that are consistent with study aims and objectives. The research strategy should include collaborations with potential end-users of cohort data such as those involved in HIV planning processes (e.g., EHE, Ryan White, CDC prevention funding) as well as service providers and provider organizations (e.g., health systems, FQHCs, harm reduction sites) or others (prevention specialists, Public Health officials, health departments, justice systems, policymakers, community organizations, etc.). Applications must thoroughly explain how the knowledge/data would be used to inform decisions, policy, practice and/or implement change. Applications need to address NIH and NIDA’s highest priority areas of research: Research Priorities | NIH Office of AIDS Research NIDA HIV Priority Areas Sites should consider their capacity to address areas of interest such as the following: System and structural level factors that lead to HIV acquisition Social determinants of HIV and substance use, including factors that increase exposure to HIV and substance use New or emerging substance use patterns and recovery approaches Long-term HIV/substance use outcomes and medical consequences such as those associated with aging and HIV Capturing the effects of systemic interventions to increase prevention, diagnosis, and treatment, including differences in HIV testing service, utilization, etc. that occur in different settings such as community organizations, FQHCs, and health systems. In addition, sites are strongly encouraged to: Expand existing populations: Increasing the representation of PLWH, ensuring the representation of sexual and gender minorities, ethnic/racial minorities and people with lived experiences, factors that contribute to HIV risk and poor treatment outcomes such as homelessness, engaging in sex work, and criminal justice involvement. EHE priority jurisdictions should be addressed in the application with epidemiologic justification provided for non-EHE jurisdictions such as rural areas affected by opioid epidemics. Demonstrate their capacity to recruit and follow populations of adequate sample size and power (i.e., >500). Smaller sample sizes need justification with respect to local epidemiology and factors such as population and service density. Sites with established cohorts should demonstrate their capacity to, and describe plans to, refresh samples and continue to recruit participants and comply with the NIH data sharing policy. The Research Strategy should: Describe how substance use in the population will be characterized i.e., specific drugs used, level and history of use, form of administration, continuum cascade of substance use, and/or changing patterns over time including initiation. Describe methods for the recruitment, enrollment, and retention of cohort participants, describing previous experience with recruitment and retention of longitudinal samples. Describe the data collection methods and their appropriateness for the variables of interest, as well as the primary analyses of data, providing a rationale for the analytic methods selected and the statistical power for major analyses. Include specific proposed data elements, such as clinical data, summary health histories, biologic specimens, socio-behavioral data, or treatment variables that will support the study aims Given the requirement of data sharing across cohort sites, the discussion should address how proposed data elements could incorporate common or shared platforms. Provide justification of the priority research domains for the cohort study and for the approaches to achieving the study aims. The study rationale should indicate how the cohort will address gaps in current NIH-funded HIV cohort research (e.g., MWCCS, CNICS, LITE) and indicate where it might complement existing cohort research. Describe experience with participation in multi-site research, particularly where data sharing was integrated into the research. Applications also should describe the administrative and organizational structure for the project and how it will facilitate attainment of the aims and objective of the proposed research. Where biospecimens are routinely collected, applications should describe procedures for processing, storage, and sharing for use by the scientific community. Document alignment with EHE plans or other appropriate HIV service plans (e.g., CDC/Ryan White planning processes) and provide a plan for engaging local decision makers, as well as document how cohort data can inform local decisions about resource allocation and service delivery. For renewal applications, applicants should provide a rationale for continued funding including information regarding any new data collection. Renewal applicants must provide plans to demonstrate program relevance and to ensure representation of current HIV/substance use epidemic patterns. Applications Not Responsive to this NOFO include: The following types of applications will be considered non-responsive and will be returned without review: Studies that do not have the capacity to adhere to data sharing requirements and data harmonizing activities with the data coordinating center (transferring data, common data elements or biorepository data sharing) as specified above. Studies with less than 500 participants without adequate justification. Applications with a primary focus on research related to end organ or systemic disease related to comorbidities such as cardiac, liver, or chronic kidney diseases, hypertension, and bone disorders. Studies that do not focus on HIV infection and substance use and/or outcomes. Plan for Enhancing Diverse Perspectives (PEDP) This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP) as described in NOT-MH-21-310, submitted as Other Project Information as an attachment (see Section IV). Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material. The PEDP will be assessed as part of the scientific and technical peer review evaluation, as well as considered among programmatic matters with respect to funding decisions.

This grant provides financial assistance to Native American tribes, Native Hawaiian organizations, and museums for the repatriation of human remains and cultural items to their rightful communities.